Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.

Bellone, Stefania

Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research 07 2018 - 3282-3291 p. digital

Publication Type: Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1557-3265

10.1158/1078-0432.CCR-17-1805 doi


Aged, 80 and over
Antibodies, Monoclonal, Humanized--administration & dosage
Antineoplastic Agents, Immunological--administration & dosage
B7-H1 Antigen--genetics
Biomarkers, Tumor
Biopsy
Computational Biology
Drug Resistance, Neoplasm
Female
Gene Rearrangement
HLA Antigens--immunology
Humans
Molecular Targeted Therapy
Mutation
Ovarian Neoplasms--diagnosis
Positron Emission Tomography Computed Tomography
Programmed Cell Death 1 Receptor--antagonists & inhibitors
Receptors, Cell Surface--genetics
Retreatment
T-Lymphocytes--drug effects
Treatment Outcome
Exome Sequencing